Bio-Techne to Present at Upcoming Investor Conferences

MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 46th Annual Health Care ConferenceMarch 3, 202611:10 AM EST Leerink Partners Global Healthcare ConferenceMarch 10, 20268:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

PRNewsWire • 12 hours ago

KMDA or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Feb 17, 2026

Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories

Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with minimal hands-on time Provides confidence for use in clinical trials and in-house test development    MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.

PRNewsWire • Feb 16, 2026

Bio-Techne Announces Changes to its Leadership Team

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment.

PRNewsWire • Feb 11, 2026

Biotech firm Bio-Techne beats quarterly estimates on strength in key unit

Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development.

Reuters • Feb 4, 2026

Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript

Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript

Seeking Alpha • Feb 4, 2026

Bio-Techne Releases Second Quarter Fiscal 2026 Results

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.

PRNewsWire • Feb 4, 2026

Bio-Techne Declares Dividend

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026.

PRNewsWire • Feb 4, 2026

Techne (TECH) Beats Q2 Earnings and Revenue Estimates

Techne (TECH) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.42 per share a year ago.

Zacks Investment Research • Feb 4, 2026

Techne (TECH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Feb 4, 2026